Lower testosterone and higher estradiol (E2) levels correlate with an increased risk of coronary artery disease and cardiovascular mortality. Testosterone replacement therapy minimizes metabolic syndrome and cardiovascular risks. Higher testosterone predicts a reduced 5-year risk of cardiovascular disease in men. Prevention of androgen (testosterone) deficiency improves cardiovascular outcomes. The severity of coronary artery stenosis is associated with lower levels of testosterone.
All of the above statements are the conclusions of major studies and publications that came out in 2011. A 15 year follow-up by Cenegenics Institute in a 20,000 patient population has demonstrated the following. Men and women that take advantage of hormone optimization, low glycemic diet with healthy fats, and get at least 15 minutes of resistance exercise enjoy a far greater quality of life, reduced fractures and dementia, reduced cardiovascular deaths, and with no increased risk of breast or prostate cancer.
PAMC has followed the Cenegenics protocols for over eleven years in managing its patients. Our experience is similar to those studies reported in the following medical journals:
- European Journal Internal Medicine, 2011 Dec
- Journal of Endocrinology Investigation, 2011 Nov
- Journal of American Cardiology, 2011 Oct
- European Journal of Endocrinology, 2011 Nov